Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov 2;3(107):107fs7.
doi: 10.1126/scitranslmed.3002878.

Epstein-Barr virus: an important vaccine target for cancer prevention

Jeffrey I Cohen  1 , Anthony S Fauci, Harold Varmus, Gary J Nabel
Affiliations

Epstein-Barr virus: an important vaccine target for cancer prevention

Jeffrey I Cohen et al. Sci Transl Med. .

Abstract

Participants at the February 2011 meeting at the U.S. National Institutes of Health on Epstein-Barr virus (EBV) vaccine research recommend that future clinical trials have two goals: prevention of infectious mononucleosis and EBV-associated cancers, facilitated by identification of disease-predictive surrogate markers.

PubMed Disclaimer

References

    1. Participants at the meeting were Richard Ambinder, Johns Hopkins University; Hugh Auchincloss, NIH; Henry Balfour, University of Minnesota; Alan Bernstein, HIV Vaccine Enterprise; Wei Bu, NIH; Corey Casper, Fred Hutchinson Cancer Research Center; Jeffrey Cohen, NIH; Lawrence Corey, Fred Hutchinson Cancer Research Center ; Martine Denise, Sanofi Pasteur; Geraldina Dominguez, NIH; Anthony Fauci, NIH; Gregory Hayes, Medimmune; Carole Heilman, NIH; Bahija Jallal, Medimmune; George Kemble, Medimmune; Rajiv Khanna, Queensland Institute of Medical Research; Elliott Kieff, Harvard Medical School; Philip Krause, Food and Drug Administration; Catherine Laughlin, NIH; Douglas Lowy, NIH; Edward Mocarski, Emory Vaccine Center; Gary Nabel, NIH; Nancy Raab-Traub, University of North Carolina; Betsy Read-Connole, NIH; Steven Reed, Infectious Disease Research Institute; Alan Rickinson, University of Birmingham, UK; Cliona Rooney, Baylor College of Medicine; Dinah Singer, NIH; Joseph Sliman, Medimmune; Harold Varmus, NIH; Fred Wang, Harvard Medical School; Amy Weiner, Gates Foundation; Jennifer Woo, Medimmune; Robert Yarchoan, NIH; and Kathryn Zoon, NIH.</other>

    1. Cohen JI. Epstein-Barr virus infection. N. Engl. J. Med. 2000;343:481–492. - PubMed
    1. Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, P. Moreels A, Haumont M, Bollen A, Smets F, Denis M. Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 2007;196:1749–1753. - PubMed
    1. Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA, Owen K, Royed C, Stevens SJ, Shroff RC, Tanday MK, Wilson AD, Middeldorp JM, Amlot PL, Steven NM. A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation. 2009;88:1025–1029. - PubMed
    1. Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, Le TT, Rosenstengel A, Nguyen T, Allworth A, Burrows SR, Cox J, Pye D, Moss DJ, Bharadwaj M. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J. Virol. 2008;82:1448–1457. - PMC - PubMed

MeSH terms

LinkOut - more resources